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Introduction
In recent years, advances in laboratory techniques have led to
a rapidly increasing use of biomarkers in epidemiological studies,
a field known as molecular epidemiology [1–5]. Biomarkers are any
substance, structure or process that can be measured in
biospecimens and may be associated with health-related out-
comes. Biomarkers of internal dose, of early biological change
and of susceptibility (see Figure 1 and Box 1 for definitions) are
used as proxies for investigating the interplay between external
and/or endogenous agents and the body. Biomarkers may
provide valuable scientific tools because of their ability to inform
biological mechanisms through the examination of early,
intermediate and late molecular and cellular events. Moreover,
a biomarker may capture several external exposure variables in a
single biologically relevant quantity, provide quantitative mea-
surements, increase statistical power or be used as an efficient and
informative intermediate outcome. Finally, biomarkers can be
used to identify susceptible individuals and to improve diagnosis
and early detection of disease as well as prediction of major
clinical outcomes in patients with a given disease. Figure 1
describes the whole spectrum of applications of biomarkers; the
scheme uses cancer as an example because this is the field in
which the conceptual framework of molecular epidemiology has
had the greatest development and numerous postulated potential
applications; however, similar concepts apply to many other
fields.
Biomarker-based measurements are not, however, problem free.
As in classical biomedical and epidemiological research, consid-
ering methodological issues concerning the design, conduct,
analysis and interpretation of the results is essential to adequately
address a research question [6]. In addition to the usual problems
of bias and confounding that affect all clinical and epidemiological
studies, particular issues when using biomarkers include (i) validity
and reliability of biomarker measurements, (ii) special sources of
bias, (iii) reverse causality and (iv) false positives as a result of
multiple testing or selective reporting. To conceive relevant and
valid studies, in biomarker-based research, we need an in-depth
understanding and integration of methodological and substantive
(i.e. biological, clinical and environmental) knowledge. Complete,
accurate and transparent reporting of study design, methods,
conduct and findings is required to allow the study to be fairly and
adequately evaluated and summarized including avoidance of
selective reporting of positive results [7–10]. Empirical evidence
suggests that the results of the most highly cited biomarker studies
across medicine almost consistently report larger effect estimates
than those reported in subsequent meta-analyses [11]. Suboptimal
reporting may also lead to inflated expectations on the
translational potential and clinical utility of findings [12]. At the
other end of the spectrum, false negatives are also a common
problem [9], and they may result from limited sample size, poor
study design or inappropriate laboratory assays [13].
The need for improved reporting of scientific research in
general led to influential statements of recommendations such as
The Guidelines and Guidance section contains advice on conducting and
reporting medical research.
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CONSORT for randomized controlled trials [14,15] and
STrengthening Reporting of OBservational studies in Epidemiol-
ogy (STROBE) statement [16]. The STROBE initiative was
established in 2004 aiming at providing guidance on how to report
observational research. The resultant STROBE statement was
simultaneously published in several medical journals in 2007
[16,17]. Its guidelines provide a user-friendly checklist of 22 items
to be reported in epidemiological studies, with items specific to the
three main study designs: cohort studies, case–control studies and
cross-sectional studies. The STROBE statement has had an
important impact. Its recommendations were adopted by several
journals, and there is evidence that they have affected the style of
result reporting [18]. However, there is also evidence of misuse of
the STROBE statement [19].
Recent advances in molecular biology and the vast amount of
data generated by high-throughput techniques (and consequent
changes and improvement in terms of epidemiology, statistical
analysis and study design) warrant implementing the STROBE
recommendations specifically for molecular epidemiology studies.
For a review of the state of the art of molecular epidemiology and
the ensuing methodological problems, see [1]. Molecular tools
(biomarkers) are also increasingly applied in epidemiology
because of new and difficult issues that are addressed, such as
the effects of chronic low-level exposures. While important
discoveries of the past – such as the role of cholesterol or tobacco
smoking – originated from studies with strong associations
identified based on single measurements, there is now a challenge
to identify weaker associations, and these require more accurate
and sensitive tools. This increases the importance of a meticulous,
comprehensive and transparent description of studies involving
biomarkers.
Herein, we propose an extension of STROBE, i.e. STROBE for
molecular epidemiology, STROBE-ME. The guidelines aim to
provide an easy-to-use checklist of items that authors may use for
reporting molecular epidemiology studies other than genetic
association studies.
Recommendations already exist for genetic association studies,
a field that has specific characteristics and requirements of
reporting which have been included in a separate recent statement
(STREGA, an extension of STROBE) [20]. There is some
Summary Points
N Advances in laboratory techniques have led to the
increasing use of biomarkers in epidemiological studies,
but the quality of reporting of such studies varies.
N The STROBE (STrengthening Reporting of Observational
studies in Epidemiology) initiative, established in 2004,
provides guidance on reporting observational epidemi-
ology studies.
N Here, the STROBE-ME (Strengthening the Reporting of
OBservational studies in Epidemiology – Molecular
Epidemiology) initiative builds on STROBE and provides
additional guidance on reporting biomarker studies.
N Specific additions relate to the collection, handling and
storage of biological samples; laboratory methods,
validity and reliability of biomarkers; specificities of
study design; and ethical considerations.
N A checklist to help authors in reporting biomarker
studies is published as supporting information (Table
S1).
Figure 1. Schematic framework on the use of biomarkers in molecular epidemiology studies. Adapted from Vineis and Perera [42].
doi:10.1371/journal.pmed.1001117.g001
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necessary overlap between the current guidelines and STREGA,
insofar as ‘susceptibility biomarkers’ are included in the present
recommendations. Communication of results of molecular epide-
miology studies is a still underdeveloped field. This paper refers
only to scientific communication of study results and does not
address the ethical problem of communicating results to single
individuals, see [21,22].
Aims and Use of the STROBE-ME Statement
The expected outcome of the present recommendations is an
improvement in the reporting of results, such that the editors,
reviewers of papers and the readers understand better what was
actually done by the authors. STROBE-ME is expected to lead to
more organized and transparent papers and to a better
understanding of both the strengths and weaknesses of the studies
in molecular epidemiology. Our recommendations do not dictate
how studies should be performed nor do they serve as a basis to
evaluate the quality of observational studies; they only try to help
improve the reporting of research. The adoption of improved
reporting standards may nevertheless have also an indirect benefit
on the quality of study design.
The parent STROBE statement is a checklist of 22 items to be
addressed when observational epidemiological studies are report-
ed. The STROBE items cover different aspects of reporting a
study: the title (one item), introduction (two items), methods (nine
items), results (five items), discussion (four items) and funding of
research (one item) [16]. The explanation and elaboration
document of STROBE [17] explains these items in detail and
provides good real-life examples in published works for their
application.
The statement proposed here is intended to be an extension of
the STROBE statement for molecular epidemiology studies. The
present recommendations are intended only for those studies in
which biomarkers are used as an explanatory variable; these
include biomarkers of exposure/internal dose, biomarkers of early
biological change and biomarkers of susceptibility (Box 1, and
Figure 1). This set of biomarkers is used as measurable proxy for
the process of the interaction between an external/endogenous
agent and the body at different biological levels. Other study
Box 1. Definitions of Terms Used in the Text
There are several definitions of biomarkers. The most
commonly adopted states that a biomarker is any substance
or biological structure that can be measured in the human
body and may influence, explain or predict the incidence or
outcome of disease [24]. According to another definition, a
biomarker is ‘a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes,
pathogenic processes or pharmacologic responses to a
therapeutic intervention’ [43]. Biomarkers are measured in
human biospecimens typically using molecular, biochemical
and cytogenetic techniques. Some investigators also include
under the biomarker umbrella measures derived from modern
imaging techniques that aim to characterize biological process,
e.g. from positron emission tomography or functional
magnetic resonance imaging. However, these biomarkers also
entail issues that are specific to image processing and
interpretation that are beyond the scope of the guidance
provided in this manuscript. Some biomarkers (but not
‘exposure biomarkers’) allow insight into the cellular processes
in the human body and serve to explore the links among
environmental/endogenous exposures, the genome, host
factors/structures and disease. Based on the concept that
there is continuity between exposure to an external agent, its
metabolism within the body and the onset of a resulting time-
delayed disease, we can distinguish three main types of
biomarkers that are able to investigate the internal process of
interaction between the external agent and the body (Figure 1).
A biomarker of exposure/internal dose is an indicator of
current and/or past exposure to environmental agents.
Biomarkers of internal dose may indicate, depending on their
nature, a recent or very recent exposure as well as a long-term
exposure. The ideal biomarker of exposure is specific, detectable
at very low concentrations, in quantitative relationship with the
level of exposure, and its levels integrate over time.
Metabolite concentrations change rapidly with a short half-
life from a few hours up to a few days and may show a large
daily intra-individual variation as well as inter-individual
variation. They may be specific for certain exposures or
integrate several types of exposure. For example, urinary 1-
hydroxypyrene concentration is a surrogate for the mea-
surement of complex PAH exposure via different exposure
routes, whereas urinary 4-(methylnitrosamino)-1-(3-pyridi-
nyl)-1-butanol (NNAL), a metabolite of 4-(methylnitrosa-
mino)-1-(3-pyridinyl)-1-butanone (NNK), and its glucuronides
are specific biomarkers of exposure to tobacco smoke. A
wide variety of highly sensitive analytical methods are used
for the detection of parent compounds and their metabolites
in human biospecimens.
Biomarkers of early biological change are biomarkers
that reflect the interaction between the external agent and
the exposed body. They usually encompass a broad and
heterogeneous category; their main advantage is that their
presence in subjects is usually more frequent than the disease
itself and they can be detected earlier, thus allowing
researchers to identify potential harm before a clinical disease
manifests. Biomarkers of early biological change include
markers of early detection of disease and also prognostic
markers if the outcome is death, recurrence or disability.
Biomarkers of susceptibility include multiple subcatego-
ries, which encompass both acquired (phenotypic) biomark-
ers and genotypic markers [2]. Examples of the former are
biomarkers of previous disease, whereas genotypic markers
include the more extensively studied category of inherited
genetic variants. Concerning the latter, an essential issue is
whether and how gene variants manifest themselves in
cellular functions and phenotypes and how they influence
individual susceptibility to environmental exposures. These
include also cellular phenotypes (such as DNA repair
capacity) applied to study differences in repair capacity in
healthy exposed populations [44]. There are ethnic and
geographical differences in the frequency distribution of
genetic variants. Various technologies have been developed
for low- and high-throughput genotyping. Additionally,
markers of acquired susceptibility need to be considered,
such as biomarkers of previous diseases or biomarkers of
previous exposures such as epigenetic changes.
Biomarkers can also be used for the prediction of the clinical
course and outcomes of disease under natural history or
under treatment. Although these clinical uses are usually
outside the scope of traditional aetiological research, this is a
very rapidly expanding literature [45–47,23] with major
challenges. Although the current recommendations could
apply to these uses, for tumor marker prognostic studies, the
reader should refer to the REMARK guidelines [7].
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designs involving biomarkers are not covered by the present
recommendations, including transitional studies of validation and
reliability of measurement.
Some items belonging to the original STROBE checklist have
been implemented for molecular epidemiology studies; other items
have been added de novo to the original checklist. The 10
implemente items include issues on study design specificities in
molecular epidemiology studies; description of relevant participant
conditions at the time of sample collection; and particular
statistical aspects if the biomarker measurements are introduced
into statistical models. The seven new specific items added to the
original STROBE checklist include biological sample collection,
storage and processing; and the laboratory methods used for the
analyses. The present extended checklist was developed as an
extension of the STROBE checklist (Table 1). The recommenda-
tions are intended to complement the existing STROBE
guidelines, not to replace them; therefore, all previously described
items concerning observational studies such as cohort, case–
control and cross-sectional studies apply to molecular epidemio-
logical studies (when appropriate).
The present statement contains a checklist of items for reporting
molecular epidemiology studies (Table 1); some explanatory text
referring to single item description; and some Boxes in which
specific aspects of molecular epidemiology are briefly addressed for
readers’ reference. Although the current recommendations could
apply also to biomarkers used for the prediction of clinical course
and outcomes of disease, for tumour marker prognostic studies the
reader should refer to the REMARK guidelines [7].
Concerning the uses of the present statement, additional details
on how the parent STROBE statement was used can be found on
the website (http://www.strobe-statement.org/). It is expected that
the statement will be adopted and referred to by journals that
publish molecular epidemiology papers, as well as by journals that
publish clinical research in which biomarkers have an important
role [23].
Development of the STROBE-ME Statement
A multidisciplinary group of epidemiologists, biostatisticians and
laboratory scientists (overall approximately 15 scientists) developed
the current recommendations. Also, editors of several specialist
journals were involved from the outset. The group met twice in
London (UK) in 2008 and 2009, once in Turin (Italy) in 2009 and
once in Ło´dz´ (Poland) in 2010; it sought external opinions from
partners of the Environmental Cancer Risk, Nutrition, and
Individual Susceptibility (ECNIS) European Network of Excel-
lence – which was the initiator of the STROBE-ME initiative.
Overall, the process lasted 3 years. While no formal process such
as a Delphi consultation was used for development, consensus was
built by circulating several versions of the statement within the
group of developers and an external circle of potential users. In all,
over 30 scientists were involved in the process.
Checklist of Items
The items that should be considered when reporting molecular
epidemiology studies are shown in Table 1 and available as
supporting information. These items are similar to those that were
originally recommended in STROBE, however, with modifica-
tions that are specific to molecular epidemiology. Later, we give a
detailed description of each item. The purpose is not to suggest
how to set up a research project but how to improve reporting of
the research to allow readers (and reviewers) to better understand
what was actually done by the researchers.
ME-1 – State the use of biomarker(s) in the title and/or in
the abstract if they contribute substantially to the findings
When one or more biomarkers are measured in an epidemi-
ological study, it may be more informative reporting this in the
title or at least in the abstract of the article. This helps the reader to
identify immediately molecular epidemiology studies and ensures a
correct indexing in electronic databases.
ME-2 – Explain in the scientific background of the paper
how/why the specific biomarker(s) have been chosen,
potentially among many others
The process leading to the choice of one or more specific
biomarkers for inclusion in a paper should be made clear in the
Introduction. Background information and rationale for the choice
of the specific biomarker(s) should be explicitly stated; also, how the
biomarker is introduced in the study design should be made explicit
(biomarker of exposure, internal dose, early biological change and
susceptibility). It should also be clarified whether the biomarker is
used as a proxy, and if so, what it is intended to be a proxy for.
ME-3 – A priori hypothesis: if one or more biomarkers are
used as proxy measures, state the a priori hypothesis on
the expected values of the biomarker(s)
When stating the objective(s) of a study according to the
STROBE guidelines [16], it might be helpful to state explicitly the
a priori hypothesis on the expected values of the biomarker(s).
ME-4 – Describe the special study designs for molecular
epidemiology (in particular nested case–control and
case–cohort) and how they were implemented
Study design details should be reported in the Methods section. For
traditional designs such as case–control, cohort and cross-sectional
studies, the STROBE recommendations can be followed, with extra
care in reporting the biological sample collection integration within
study design; for nested case–control and case–cohort studies,
selection criteria for cases and controls, sampling frame and matching
criteria should be reported with extra care, as they represent a main
potential source of bias in these study designs (see Box 2). In addition
to matching criteria for individuals, all methods used for selecting or
matching biological samples (i.e. by storage time and by batch) should
be reported. Also, it is recommended to describe briefly the cohort in
which nested studies were implemented, in terms of description of the
population, sampling, outcome ascertainment, follow-up period,
number of subjects lost to follow-up and primary objective for which
the cohort was established.
ME-4N1 – Report on the setting of the biological sample
collection; amount of sample; nature of collecting
procedures; participant conditions; time between sample
collection and relevant clinical or physiological endpoints
An accurate description of the sample collection and shipment is
necessary to enable the reader to evaluate potential sources of bias
or errors in the biomarker measurement and for ensuring an
appropriate reproducibility of the scientific experiment (see Box 3).
The following items should be reported: (i) the setting of the
biological sample collection (place, time of the day, time of the
year, laboratories involved, personnel involved, etc.); (ii) amount/
volume/size of sample(s); (iii) nature of the collecting procedure
(anticoagulant involved, e.g. heparin, EDTA) (iv) if the participant
is healthy, participant condition at the sample collection (fasting
status, position, etc.) when appropriate; (v) if participants are not
healthy individuals in stable physiological conditions, then report
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Table 1. The Strengthening the Reporting Observational studies in Epidemiology – Molecular Epidemiology (STROBE-ME)
Reporting Recommendations: Extended from STROBE statement.
Item
Item
number STROBE Guidelines
Extension for Molecular Epidemiology
Studies (STROBE-ME)
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the
title or the abstract
ME-1 State the use of specific biomarker(s)
in the title and/or in the abstract if they
contribute substantially to the findings
(b) Provide in the abstract an informative and balanced summary
of what was done and what was found
Introduction
Background rationale 2 Explain the scientific background and rationale for the investigation
being reported
ME-2 Explain in the scientific background of
the study how/why the specific biomarker(s)
have been chosen, potentially among many
others (e.g., others are studied but reported
elsewhere, or not studied at all)
Objectives 3 State specific objectives, including any pre-specified hypotheses ME-3 A priori hypothesis: if one or more
biomarkers are used as proxy measures, state
the a priori hypothesis on the expected
values of the biomarker(s)
Methods
Study design 4 Present key elements of study design early in the paper ME-4 Describe the special study designs for
molecular epidemiology (in particular nested
case/control and case/cohort) and how they
were implemented
Biological sample
collection
ME-4.1 Report on the setting of the
biological sample collection; amount of
sample; nature of collecting procedures;
participant conditions; time between sample
collection and relevant clinical or
physiological endpoints.
Biological sample
storage
ME-4.2 Describe sample processing
(centrifugation, timing, additives, etc).
Biological sample
processing
ME-4.3 Describe sample storage until
biomarker analysis (storage, thawing,
manipulation, etc).
Biomarker biochemical
characteristics
ME-4.4 Report the half-life of the biomarker,
and chemical and physical characteristics
(e.g., solubility).
Setting 5 Describe the setting, locations, and relevant dates, including
periods of recruitment, exposure, follow-up, and data collection
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and
methods of selection of participants. Describe methods of follow-up
Case-control study—Give the eligibility criteria, and the sources and
methods of case ascertainment and control selection. Give the
rationale for the choice of cases and controls
Cross-sectional study—Give the eligibility criteria, and the sources
and methods of selection of participants
ME-6 Report any habit, clinical conditions,
physiological factor, or working or living
condition that might affect the
characteristics or concentrations of the
biomarker
(b) Cohort study—For matched studies, give matching criteria and
number of exposed and unexposed
Case-control study—For matched studies, give matching criteria
and the number of controls per case
Variables 7 Clearly define all outcomes, exposures, predictors, potential
confounders, and effect modifiers. Give diagnostic criteria, if
applicable
Data source/measurement 8 For each variable of interest, give sources of data and details of
methods of assessment (measurement).
Describe comparability of assessment methods if there is more
than one group
ME-8 Laboratory methods: report type of
assay used, detection limit, quantity of
biological sample used, outliers, timing in the
assay procedures (when applicable) and
calibration procedures or any standard used
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If
applicable, describe which groupings were chosen, and why
Statistical methods 12 (a) Describe all statistical methods, including those used to control
for confounding
ME-12 Describe how biomarkers were
introduced into statistical models
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Item
Item
number STROBE Guidelines
Extension for Molecular Epidemiology
Studies (STROBE-ME)
(b) Describe any methods used to examine subgroups and interactions
(c) Explain how missing data were addressed
(d) Cohort study—If applicable, explain how loss to follow-up was
addressed
Case-control study—If applicable, explain how matching of cases and
controls was addressed
Cross-sectional study—If applicable, describe analytical methods
taking account of sampling strategy
(e) Describe any sensitivity analyses
Validity/reliability of
measurement and internal/
external validation
ME-12.1 Report on the validity and reliability
of measurement of the biomarker(s) coming
from the literature and any internal or
external validation used in the study.
Results
Participants 13 (a) Report the numbers of individuals at each stage of the study—
e.g., numbers potentially eligible, examined for eligibility, confirmed
eligible, included in the study, completing follow-up, and analysed
ME-13 Give reason for loss of biological
samples at each stage
(b) Give reasons for non-participation at each stage
(c) Consider use of a flow diagram
Descriptive data 14 (a) Give characteristics of study participants (e.g., demographic, clinical,
social) and information on exposures and potential confounders
(b) Indicate the number of participants with missing data for each
variable of interest
(c) Cohort study—Summarise follow-up time (e.g., average and
total amount)
Distribution of biomarker
measurement
ME-14.1 Give the distribution of the
biomarker measurement (including mean,
median, range, and variance)
Outcome data 15 Cohort study—Report numbers of outcome events or summary
measures over time
Case-control study—Report numbers in each exposure category,
or summary measures of exposure
Cross-sectional study—Report numbers of outcome events or
summary measures
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted
estimates and their precision (e.g., 95% confidence interval).
Make clear which confounders were adjusted for and why they
were included
(b) Report category boundaries when continuous variables were
categorized
(c) If relevant, consider translating estimates of relative risk into
absolute risk for a meaningful time period
Other analyses 17 Report other analyses done—e.g., analyses of subgroups and
interactions, and sensitivity analyses
Discussion
Key results 18 Summarise key results with reference to study objectives
Limitations 19 Discuss limitations of the study, taking into account sources of
potential bias or imprecision. Discuss both direction and magnitude
of any potential bias
ME-19 Describe main limitations in
laboratory procedures
Interpretation 20 Give a cautious overall interpretation of results considering
objectives, limitations, multiplicity of analyses, results from
similar studies, and other relevant evidence
ME-20 Give an interpretation of results in
terms of a-priori biological plausibility
Generalisability 21 Discuss the generalisability (external validity) of the study results
Other information
Funding 22 Give the source of funding and the role of the funders for the present
study and, if applicable, for the original study on which the present
article is based
Ethics ME-22.1 Describe informed consent and
approval from ethical committee(s). Specify
whether samples were anonymous,
anonymised or identifiable
doi:10.1371/journal.pmed.1001117.t001
Table 1. Cont.
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the relevant aspects of the health status and clinical conditions of
the participants [24,25]; (vi) in all instances, consider reporting the
time between sample collection and relevant clinical or physio-
logical endpoints that might have affected the characteristics or
concentrations of the biomarker [26]. In particular, report any
relevant characteristic of the participants, which might influence
the biomarker levels in any known or unknown way. For example,
position of the study subjects, such as orthostatism decreases
plasma volume, so that proteins and cholesterol levels can be
lowered by 5–15% relative to the supine position.
Detailed information on all critical steps that might have altered
the biological samples or influenced the final biomarker measure-
Box 2. Specificities of Study Design for
Molecular Epidemiology: Nested Case–
Control Studies and Case–Cohort Studies
Molecular epidemiology uses the same study designs as
the general epidemiology, but some variants are more
common. In particular, case–control studies nested in
cohorts and case–cohort studies are frequently used to
avoid extensive and costly measurements in large cohorts.
In nested case–control studies derived from established
cohorts, controls are usually matched for age and sex, and
also for time variables related to sample collection and
disease onset. The method of control selection in these
studies is ‘incidence density’ sampling, and an incidence
risk ratio is estimated. Controls may develop the disease of
interest subsequently to the diagnosis of the case, but
they represent the cohort set at risk of developing the
disease when each case occurs [24]. The criteria for case
inclusion and control matching and selection and their
rationale should be reported [1].
In case–cohort studies, unmatched controls come from a
sample of the cohort at inception without being matched
to cases on time to outcome. The method for control
selection in these studies is based only on the population
at baseline, without regard to failure times, and a risk ratio
is estimated [24,1].
Both study designs share the important feature that cases
and controls come from the same cohort study: recall bias
is not of concern if exposure assessment was carried out
before disease onset; nonparticipation bias is avoided
because rapidly fatal cases have the same probability of
inclusion as others; and reverse causation becomes less
likely as biological samples were collected before the
onset of the clinically documented disease. The nested
case–control study tends to be more efficient than the
case– cohort study in selecting controls to address
confounding. In case–cohort studies, however, the same
sample of controls can be compared to different samples
of cases (thus different outcomes can be studied). Also, as
the sub-cohort is a random sample of the whole cohort,
prevalence of exposure can be estimated and external
comparisons can be made.
The main concerns regarding nested case–control studies
are that controls are not representative of the cohort
population and they have few other uses, so the
investment in biomarker analyses cannot be leveraged
for other research. On the other hand, case–cohort studies
rely on the assumption that exposure can be equally well
measured in the sub-cohort as in the cases. However, three
issues regarding biomarker validity make this assumption
questionable: batch effects, the storage effect and freeze–
thaw cycles. There are technological and staffing limits to
how many samples can be analysed in one go so samples
are run in batches or groups. Conditions of the analyses
should not vary by batch, but it is clear that for many
biomarker measurements this is not true, i.e. there are
substantial batch effects (laboratory variation). Also, not all
biomarker targets are stable at the usual storage
temperature (280uC), and when samples freeze and thaw,
the pH and ionic balance of the liquid phase of the sample
can be very different from the natural condition of the
sample. Changes in pH and ionic balance can degrade
biomarker targets. For these reasons, it may be necessary
to include matching by length of storage, batch and
freeze–thaw cycles [1].
Box 3. Collection, Handling and Storage of
Biological Samples
Several types of human biospecimens can be collected for
carrying out molecular epidemiology studies. Blood sam-
ples may be stored as a whole or separated into sub-
fractions and blood components (red blood cells, serum,
plasma, buffy coat and white blood cell sub-fractions).
White blood cells contained in the buffy coat are the most
widely used source of DNA. Urine can be used as a solution
of excreted parent compounds and metabolites to be
measured, or as a source of exfoliated cells of the urinary
tract. Collection and primary processing are performed
accordingly. Other human tissue specimens used in
molecular epidemiology studies include body fluids (i.e.
cerebrospinal fluids), cell washes (i.e. buccal wash or swabs),
epithelial smears, surgical material, nails and hair. Each step
in collection, storage, thawing, manipulation and laboratory
analysis can introduce errors that may lead to bias and
variability. Random error, if evenly distributed in study
subgroups, is likely to attenuate or eliminate differences.
Systematic errors (e.g. differential clinical conditions,
handling or storage of biological samples from cases and
non-cases) may generate spurious associations.
Timing of collection often influences the true biomarker
level. For example, hormones have hourly, daily or monthly
cycles. Prolonged venipuncture can induce release of
prolactin or increase white blood cell counts. A very narrow
needle causes haemolysis. Several additives can be added to
blood, e.g. metaphosphoric acid for vitamin C; anticoagu-
lants such as heparin, EDTA or citrate are needed for plasma
collection (i.e. not needed if only serum is collected). There
may be disadvantages: heparin binds to many proteins and
influences T-cell proliferation; EDTA interferes with cytoge-
netic analyses. Citrate-stabilized blood affords better quality
of RNA and DNA than other anticoagulants. Other additives
include protease inhibitors and RNAse inhibitors to avoid
degradation of proteins and RNA, respectively.
The goals of proper sample storage are to ensure (i)
standardized procedures for all phases; (ii) minimal loss or
degrading of material (e.g. because of malfunctioning of
freezers); (iii) optimal preservation of material; (iv) blinding,
whenever appropriate; (v) easy access to the material when
needed; (vi) easy matching of biological material with
individual identity; (vii) respect of confidentiality; and (viii)
anticipation of emergencies. Stability of the compounds to
be measured depends on the type of measurement and
temperature of storage: for example, fatty acids should be
measured within 2 weeks when samples are stored at 4uC,
within a few months when stored at220uC, up to one year
when stored at280uC. A few studies have been conducted
on the stability of different analytes, but the literature is far
from being exhaustive.
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ment should be identified and reported accordingly in the
Methods section.
ME-4N2 – Describe sample processing (centrifugation,
timing, additives, etc.)
A comprehensive description of all steps of sample processing is
needed in the Methods section to assess experimental reproduc-
ibility. This description ranges from manual handling of samples to
specific machinery used for laboratory processing (see Box 3).
When a well-established technique is used, the main process can
be referred to by quoting the article where the technique is
described and any variation from the initially described laboratory
technique should be explicitly stated.
ME-4N3 – Describe sample storage until biomarker
analysis (storage, thawing, manipulation, etc.)
Particularly in nested case–control and case–cohort studies,
biomarkers can be measured in biological samples stored for
extended durations; sometimes, samples may have already
undergone freeze–thaw cycles. As these processes can partially
alter the biomarker values under examination, it is important to
report in the Methods section any manipulation that the biological
samples may have undergone, together with a detailed description
of how the samples were stored.
ME-4N4 – Report the half-life of the biomarker and
chemical and physical characteristics (e.g. solubility)
For new biomarker(s) only, some basic biochemical informa-
tion relevant to the interpretation of the measured values should
be reported in the Methods section. This includes bioche-
mical and biophysical characteristics that might be relevant
when interpreting the results, such as half-life, solubility or
lipophilicity.
ME-6 – Report any habit, clinical condition, physiological
factor, or working or living condition that might affect
the characteristics or concentrations of the biomarker
Report any relevant characteristic of the participants, which
might influence the biomarker levels in any known or unknown
way [24]. For example, exposure to air pollution [27] or
seasonality [28] might influence DNA adduct levels in healthy
subjects; similarly, type of diet [29,30] or amount of sunlight
exposure [28,31] might influence DNA damage biomarkers in
healthy subjects.
ME-8 – Laboratory methods: report type of assay used,
detection limit, quantity of biological sample used, outliers,
timing in the assay procedures (when applicable) and
calibration procedures or any standard used
The methods used in the laboratory for biomarker analyses
should be described in detail in a dedicated section of the
Methods. Particular care should be taken to describe new or
modified techniques, while for a well-established technique, the
main process can be referred to by quoting the article where the
technique is described, and any variation from the initially
described laboratory technique should be explicitly stated. Any
calibration procedures or external standards used in the laboratory
(or for comparing data coming from different laboratories) should
also be described. The definition of ‘outlier’ should be clearly given
(for example, whether it is based on pathophysiological, technical
or statistical grounds).
ME-12 – Describe how biomarkers were introduced into
statistical models
Usually, statistical methods that apply to biomarkers do not
differ from those used in other branches of epidemiology and
clinical research. Here, we mainly refer to specificities of
biomarker research. When continuous variables are used (a very
common occurrence for biomarkers), testing for linearity may be
useful when the marker is used as a covariate, in addition to
checking other statistical model assumptions when it is used as an
outcome. Statistical manipulation of a variable derived from
biomarker measurement values should be described in detail as for
other variables included in the statistical models. Whether the
variable is introduced as a continuous or categorical variable (and
if categorical what criterion has been used for identifying cut-off
points); whether extreme values have been excluded, and with
which criteria; whether the original variable has been log
transformed or manipulated in any other way; whether crude
measurements or corrected/adjusted values (e.g. ratios to binding
hormones and creatinine-adjusted values) were analysed; and how
samples with nondetectable biomarker levels were dealt with (e.g.
considered as zero, as the detection limit, as half of that level or
imputed) should be clearly stated.
ME-12N1 – Report on the validity and reliability of
measurement of the biomarker(s) coming from the
literature and any internal or external validation used in
the study
Validity and reliability of biomarker(s) measurement should be
reported when every specific biomarker is introduced (see Box 4).
Measurement error has several components, and there is ambiguity
on the use of the term, because ‘error’ encompasses both true
‘variations’ and ‘mistakes’. ‘Analytical’ measurement errors origi-
nate from the laboratory technique(s), including between-batch
variation, while other sources of ‘pre-analytical error’ include
variations in the individuals or the samples that are investigated [1].
Ideally, the inter-individual, intra-individual and inter-laboratory
variations should be reported for each biomarker to enable the
reader to understand the potential source of error for each specific
biomarker. Literature-based reliability estimates should be properly
referenced. When these figures are not available from the literature,
this should also be stated. If aspects of the validity and reliability
have been determined as part of the current study, the methods and
process should be briefly stated. When a specific laboratory
procedure or method for biomarker measurement has been
standardized across laboratories for facilitating the comparability,
this should be clearly stated [32,33].
Biomarker measurement validation is particularly important
when a new biomarker is described. Without information on
measurement error, intra-individual variation and inter-individual
variation biomarker studies are uninterpretable. Also, variation by
batch is usually very relevant and may create artifactual
relationships [34]. For more detailed presentation of validity and
reliability issues, see Box 4.
Besides validity and reliability of biomarker measurements, it is
increasingly recognized that the study results are likely to be more
credible when they have been reproduced by some additional
validation process, either internally (e.g. by cross-validation) or
preferably with external independent validation in samples that are
totally different from those where the biomarker was first tested
[35]. All attempts at internal and external validation carried out by
the authors should be reported in detail in the Methods section, and
the respective results should be shown in the Results section.
PLoS Medicine | www.plosmedicine.org 8 October 2011 | Volume 8 | Issue 10 | e1001117
ME-13 – Give reasons for the loss of biological samples at
each stage
Loss of specimens, non-evaluable samples (because of poor
quality) or assay failures are common occurrences. When some
samples are not included in the final analysis because of problems
in sample quality, quantity, availability, timing of sample collection
or technical failure give detailed reasons. This will help in tracking
the final sample size and the reasons for sample exclusions.
ME-14N1 – Give the distribution of the biomarker
measurement (including mean, median, range and
variance)
An appropriate description of the biomarker measurement
distribution is of help for interpreting results and for comparing
similar biomarker measurements by other scientists. It also often
facilitates the biological interpretation of the results. A graph of the
full distribution may be useful (when relevant, also by exposure
status or case/control status).
ME-19 – Describe main limitations in laboratory
procedures
Potential and actual limitations met in laboratory procedures
should be described in detail in the Discussion. It may be helpful
also to report whether the limitation would likely have introduced
a random or systematic error and, if systematic, to suggest in
which direction this might have biased the results. Validation of
results of biomarker studies is of major importance, and the
discussion should address whether any validation procedure was
used in the study [36].
Box 4. Biomarker Validity and Reliability
To achieve an accurate estimate of the association between
a biomarker and a disease, reliable and valid measurements
of exposure, covariates (potential confounders and effect
modifiers) and outcomes are needed [48]. Validity is defined
as the (relative) lack of systematic measurement error when
comparing the actual observation with a standard, which is a
reference method representing the ‘truth’. While validity
entails a ‘standard’, reliability (reproducibility and repeatabil-
ity) concerns the extent to which any measuring procedure
yields the same results in repeated experiments [49].
Validity and reliability are separate entities: a measurement
may be perfectly reliable (reproducible in different laborato-
ries and repeatable at different times), but consistently wrong,
i.e. far away from the true value; conversely, another one can
be unbiased on average, but unreliable if the measurements
scatter widely around a true value. Both validity and reliability
are important; however, as validity is often not measurable,
reliability is sometimes used (incorrectly) as a surrogate.
Timing is also a relevant aspect: inferences about the
meaning of biomarker measures are often strictly time
specific, as time influences the results in several different
ways [49]. For example, while DNA genetic variants are the
same for each individual through one’s life time, their
epigenetic profile may change markedly over time.
Biomarker variability influences associations with the end-
point, thus needs to be assessed and reported upon. A single
measure of a biomarker for one individual will be affected by
(i) variability within subject (intra-subject); (ii) biological
sample variation (i.e. variation depending on the frame of
biological sample collection); and (iii) laboratory variation.
Intra-individual variation is sometimes so large that between-
individual variation (usually the unit of interest) is hard to
detect. A single biological measurement (assume that this is
in the absence of laboratory variation) represents the
biomarker level/status at a particular time. The biomarker
may undergo diurnal, monthly, seasonal or longer variations,
e.g. prolactin has a circadian rhythm, oestrogens vary through
the menstrual cycle, biomarkers related to recent fruit and
vegetable intakes may have seasonal variations. Other
biomarkers are more stable, i.e. have less intra-individual
variation, and thus, a single measure/sample is usually
sufficient (such as mercury in hair, SNPs – single nucleotide
polymorphisms). Variation in exposure to other compounds
may have influence on the marker level. Intra-individual
variability can be measured only if repeated samples from
the same individual are collected [50]. Depending on the
research question, a measure of a recent, short-term or
instantaneous level may be desired (e.g. current CD4 count in a
HIV patient), or an average level over a specified time interval
(e.g. usual vitamin D level).
Biological sampling variation is related to the circumstances
of biological sample collection. For example, hyperprolifera-
tion of colonic cells is extremely variable at different
segments of the colon mucosa. Therefore, not only the
intra-subject variation over time is important, because of the
varying exposure to agents that induce cell proliferation, but
also the measurements are strongly influenced by how and
where the mucosa is sampled from.
Laboratory measurements can have many sources of error, in
particular two general classes of laboratory errors: those that
occur between analytical batches and those that occur
within the batches. Handling, processing and storing of
specimens may contribute to errors. Laboratory procedures
need to be in place to minimize such variation and avoid
biases. Quality control procedures such as the inclusion of
laboratory quality control samples and blinded split samples
are used to assess the extent of these errors. There should be
no identifiers that relate the sample to any other character-
istics of the individual from whom it came and in particular
of their disease status or any other factor.
The errors of biomarker measurement may have different
impact depending on their error distribution. If the epidemi-
ological study has been conducted blindly, i.e. the laboratory
analyses have been carried out with no knowledge of the
exposed/unexposed or diseased/healthy status of the subjects,
the measurement error is expected to be evenly distributed
across strata of exposure or disease. However, this is true only if
the error is equally distributed across the scale of the exposure.
This kind of misclassification leads to underestimation of the
risk ratio because of a ‘blurring’ of the relationship between
exposure and disease. Both underestimation and overestima-
tion of the association of interest may occur when misclassi-
fication is not evenly distributed across the study variables [51].
Individuals with extreme biomarker levels may be excluded, or
sensitivity analyses are carried out with and without them to
check whether they overly influence the general findings.
Themost important singlemeasureof biomarker reliability is the
intra-class correlation coefficient (ICC). This is a quantitative
measurement of the between-person variance divided by the
total (between plus within-subject) variance [52]. It describes
howstronglymeasurements taken in the samesubject resemble
each other in comparison with the inter-individual variance.
PLoS Medicine | www.plosmedicine.org 9 October 2011 | Volume 8 | Issue 10 | e1001117
ME-20 – Give an interpretation of results in terms of a
priori biological plausibility. Results should be interpreted
in the light of the mechanism(s)
Of action of the biomarker(s) and of the a priori hypothesis, thus
offering a biologically plausible interpretation. It may be useful to
stress the added value of the biomarker(s) in explicating the
biological mechanism underlying the association reported.
ME-22N1 – Describe informed consent and approval from
ethical committee(s). Specify whether samples were
anonymous, anonymized or identifiable
Molecular epidemiology poses special ethical issues that are
summarized in Box 5.
Discussion
Transparent reporting is essential in epidemiology as in science
in general, and in molecular epidemiology in particular. Given
that the use of biomarkers has raised great expectations in terms of
potential elucidation of disease aetiology and pathogenesis, it is
important to raise awareness on the intrinsic limitations of
biomarker measurements. In particular, measurement error is a
common problem and can cause both false-negative and false
positive results [9]. Also, the lack of a formal study design may
substantially impair the interpretation of the results, and selective
reporting of results can be detrimental.
The present STROBE-ME checklist should strengthen primar-
ily the reporting and interpretability of molecular epidemiology
studies, if used widely and systematically. It has been developed
based on two strong foundations: (i) the well-established STROBE
collaboration and the related statement and (ii) an ECNIS working
group formed by epidemiologists, biostatisticians and laboratory
scientists with extensive experience in the field of molecular
epidemiology and biomarker analyses.
We hope that these guidelines will improve the quality of
reporting of molecular epidemiology and other biomarker based
research, including studies conducted within the growing number
of biobanks and of biomonitoring projects.
The ethical duty of researchers includes reporting findings with
accuracy, completeness and transparency, and in sufficient detail
to allow the scientific community to consider them adequately,
assess their strengths and weaknesses and make fair comparisons.
Well-reported published studies can contribute to and be
summarized with an evidence-based approach in an appropriate
manner (i.e. on sound scientific grounds) to arrive at unbiased
conclusions that lead to better knowledge and the advancement of
citizens’ health [37,38].
Finally, we would like to stress that these recommendations, as
the original STROBE statement and other guidelines on reporting
Box 5. Ethical Considerations
Legal issues related to the use of stored human biological
material are contained in a European guideline issued by the
Council of Europe (http://www.coe.int). In the United States, a
useful website is http://nih.gov/sigs/bioethics. When incorpo-
rating biospecimen-derived measurements, the following
requirements should be met: follow respectful protocols in
eliciting information; avoid harm to participants; secure
proper informed consent, manage anonymization of inter-
linking databases; establish confidentiality and security
safeguards; develop proper responses to requests for personal
data by various parties; devise sound data access, ownership
and intellectual property policies; be clear about whether and
how individuals will be informed of findings that might be
medically helpful for them; and arrange supervision by
research ethics and privacy protection bodies [53].
Clearly, each of these requirements would need extensive
comments. In particular, how ‘broad’ should the consent be?
On the one hand, a broad consent (e.g. ‘the biological
samples will be used for the identification of gene variants
that may predispose to chronic diseases’) implies a greater
freedom of the researcher, who is not obliged to collect
further consent forms each time a new gene is investigated.
On the other hand, such a generic informed consent form
explains very little to the recruitees.
The concept of informed consent was initially formulated in
the Declaration of Helsinki in 1964, with the latest revision in
2000 (http://www.wma.net). Recent developments in molec-
ular epidemiology tend to overcome the conflict between
‘broad’ and ‘narrow’ consent forms, introducing the idea of a
‘two-level consent’, i.e. a relatively broad procedure at first,
followed by a more specific and detailed approach when
studies on single genes/biomarkers are conducted.
For example, there is a broad agreement that low-penetrant
variants that are common in the general population and are
associated with a slight increase in the risk (interacting with
environmental exposures) should not be subject to strict rules
as far as ethical implications are concerned. In fact, knowledge
of presence or absence of a single allele involved in metabolic
pathways neither allows the carrier to modify her/his risk
profile substantially nor allows the researcher to identify other
members of the family, which would violate confidentiality.
The case of highly penetrant gene variants is different: e.g., the
identification of the carrier of a rare mutation allows the
researchers to identify other family members possibly affected,
with potential detrimental effects (e.g. on insurance policies).
The same reasoning applies to biomarkers. The majority of
biomarkers used in observational epidemiological research are
of little utility to the subjects participating in the research, when
taken alone. This is particularly true for the biomarkers of
exposure, but also some biomarkers of early biological change/
effect may not be meaningful when extrapolated from the
research context; for example, DNA adduct level is difficult to
interpret at a personal level. Researchers should have a clear
view of the practical implications of testing for the study
subjects, and in particular what to do in each of these
situations: when no effective treatment is possible; when
treatment is available with close balance of favourable/
unfavourable effects; and effective treatment is available with
scarce unfavourable effects. Similar considerations apply to
biomarkers, which can be weakly or strongly associated with
diseases and less or more associated with family history.
Anonymization of information is another difficult issue. First,
there is a problem of definitions: ‘identifiable’ is a sample
with name or social security number on it; ‘coded’ is a
sample with a code that allows relatively easy identification
of the person; ‘encrypted’ is a sample with a code that does
not allow easy identification of the person, but this is
possible with extra effort; finally, ‘anonymous’ is a sample for
which there is no possibility of linking to a person. Clearly, a
really anonymous collection of samples is of very little use for
epidemiological research, which is based on follow-up and
linkage of laboratory data and health-related data.
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research [7,14,16,20], are evolving documents requiring continuous
feedback, reassessment and refinement. The STROBE-ME guide-
lines will be published on the STROBE website (http://www.
strobe-statement.org) where a forum for discussion and improve-
ment of the checklist and related material will be available.
Guidance documents should also be appraised for their eventual
impact. The EQUATOR initiative [39–41] has found that only
17% of the surveyed guideline developers performed a formal
evaluation of the impact. We will engage journal editors in
attempts to evaluate the impact of the present statement in the
long run.
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